Insider buying last 90 days
No open-market insider purchases were filed for PEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Penumbra's most recent quarter, reported 29 October, showed earnings of $1.07 per share against an estimate of $1.20, and the stock's reaction to that report was muted at 0.2%. With no fresh headlines this week, the stock's standing reflects that recent print and its position relative to its own trend lines rather than any new catalyst.
Penumbra closed at $321.85, up 0.8%, sitting between its 50-day average of $320.24 and 200-day average of $326.46, a mixed trend picture. The GekkoIndex reads 58.8, placing the stock in the Neutral zone. Shares trade 4.5% below Gekko Fair Value of $337.16, within the 52-week range of $259.14 to $362.41. Over the past year the stock has returned 21.6%, though its three-month return is -1.4% and six-month flat at 0%.
The next earnings date falls on 24 February 2027, 106 days out and beyond a typical 20-trading-day holding window, with prior reports showing an average absolute reaction of 5.6% and 5 beats across the last 8 quarters. No insider, Congress or unusual options activity appears in their respective 90-day and 30-day windows, and one trailblazer holder is recorded. Seasonally, the next 20 trading days have averaged an 8.4% gain over 5 years, rising in 4 of those years. Coverage remains limited to 2 firms, both at hold, with a consensus target of $362.54 implying 12.6% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Penumbra scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
Averages disagree
Close $320.91 sits between the 50-day ($320.15) and 200-day ($325.71) averages, or the averages disagree.
See the chart59.1, Neutral
Reading 59.1 is in the Neutral zone.
See the GekkoIndex4.8% below
Price is within 5% of Gekko Fair Value (4.8% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+8.4% on average
From this point in the calendar, the next 20 trading days averaged +8.4% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Penumbra closed at $320.91 on Nov 13, 2026, +14.5% over the past year, inside a 52-week range of $274.20 to $362.41.
Use the left and right arrow keys to read daily values.
Put PEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Penumbra designs, manufactures and sells medical devices used to treat vascular and neurological conditions, with products sold across the United States and in other countries. It is best known for its thrombectomy systems, tools that use vacuum or mechanical aspiration to clear blood clots from vessels in the body and brain, including devices such as the Indigo System, Lightning Flash and Lightning Bolt 7.
Beyond thrombectomy, Penumbra makes a wide set of related tools, among them guide catheters and delivery catheters for accessing blood vessels, an integrated reperfusion system for mechanical thrombectomy, coiling systems used to treat aneurysms and other vascular lesions, embolization devices for peripheral use, and a neurosurgical device for removing fluid and tissue from the brain. These products reach hospitals and medical practitioners through the company's own direct sales teams as well as through outside distributors.
Penumbra was incorporated in 2004 and operates out of Alameda, California. Its shares are listed on the NYSE under the ticker PEN.
Penumbra’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.1, in the Neutral zone, down 1.7 points over five sessions.
Down 1.7 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | +2.2% | +7.4% | ||
| Accumulation | 296 | 0.0% | −0.7% | ||
| Neutral (current zone) | 337 | +0.5% | +2.2% | ||
| Distribution | 36 | −1.3% | −1.8% | ||
| Selling | 1 | Too few readings yet | |||
Average PEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Penumbra trades 4.8% below Gekko Fair Value of $337.11, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Penumbra shares are worth, recalculated every trading day.
$337.11
Gekko Fair Value, Nov 14, 2026
4.8% below fair value · About fair value
At the end of Aug 2026 the price was 7.0% below the estimate.
No open-market insider purchases were filed for Penumbra, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in PEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Penumbra has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds PEN.
Penumbra reports on Feb 24, 2027, after the close (101 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 24, 2027
Expected after the close, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.07 est $1.20 | $410.1M est $401.4M | +0.2% |
| Jul 30, 2026 | $0.88 est $1.15 | $390.0M est $389.6M | +0.3% |
| May 6, 2026 | $1.01 est $1.06 | $374.8M est $370.5M | +0.2% |
| Feb 25, 2026 | $1.18 est $1.10 | $385.4M est $361.9M | +0.7% |
| Nov 5, 2025 | $0.97 est $0.93 | $354.7M est $341.0M | +12.6% |
| Jul 29, 2025 | $0.86 est $0.81 | $339.5M est $341.3M | +10.4% |
| Apr 23, 2025 | $0.83 est $0.67 | $324.1M est $327.3M | +7.6% |
| Feb 18, 2025 | $0.97 est $0.89 | $315.5M est $311.6M | +13.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Penumbra is $362.54, +13.0% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | UBS | $374 | +16.5% |
| Oct 30 | RBC Capital | $374 | +16.5% |
| Oct 5 | Citi | $350 | +9.1% |
| Oct 1 | RBC Capital | $374 | +16.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Penumbra averaged +8.4% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 4 of 5 |
| Next 10 trading days | +2.3% | 4 of 5 |
| Next 15 trading days | +4.5% | 4 of 5 |
| Next 20 trading days | +8.4% | 4 of 5 |
| Next 30 trading days | +11.1% | 5 of 5 |
For scale, PEN’s typical 20-trading-day move in either direction is about 6.9%.
Penumbra’s market cap is $12.65B, with a P/E ratio of 80.8 and revenue of $1.56B over the last twelve months.
Penumbra’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Penumbra’s market cap is $12.65B at the Nov 13, 2026 close of $320.91, with 39.41M shares outstanding. The shares trade on a P/E ratio of 80.8.
The consensus analyst 12-month price target for Penumbra is $362.54, +13.0% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Penumbra is about fair value: the Nov 13, 2026 close of $320.91 is 4.8% below Gekko Fair Value of $337.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Penumbra is expected to report on Feb 24, 2027, after the market closes (101 days away). Analysts expect earnings of $1.44 per share on revenue of $430.4M. Penumbra beat the earnings estimate in 5 of its last 8 reports, moving 5.6% on average across the report.
Penumbra’s 52-week high is $362.41 and its 52-week low is $274.20; it closed at $320.91 on Nov 13, 2026, +14.5% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.